GP6

Summary

GP6 (glycoprotein VI platelet, HGNC:14388) is a protein-coding gene on chromosome 19q13.42, encoding Platelet glycoprotein VI (Q9HCN6). Collagen receptor involved in collagen-induced platelet adhesion and activation.

This gene encodes a platelet membrane glycoprotein of the immunoglobulin superfamily. The encoded protein is a receptor for collagen and plays a critical role in collagen-induced platelet aggregation and thrombus formation. The encoded protein forms a complex with the Fc receptor gamma-chain that initiates the platelet activation signaling cascade upon collagen binding. Mutations in this gene are a cause of platelet-type bleeding disorder-11 (BDPLT11). Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 51206 — RefSeq curated summary.

At a glance

• Gene–disease (curated): platelet-type bleeding disorder 11 (Definitive, ClinGen)
• GWAS associations: 21
• Clinical variants (ClinVar): 354 total — 13 pathogenic, 5 likely-pathogenic
• Phenotypes (HPO): 10
• Druggable target: yes — 9 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_016363

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14388
Approved symbol	GP6
Name	glycoprotein VI platelet
Location	19q13.42
Locus type	gene with protein product
Status	Approved
Aliases	GPVI
Ensembl gene	ENSG00000088053
Ensembl biotype	protein_coding
OMIM	605546
Entrez	51206

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 retained_intron

ENST00000310373, ENST00000333884, ENST00000417454, ENST00000465648, ENST00000468239, ENST00000906006

RefSeq mRNA: 3 — MANE Select: NM_016363 NM_001083899, NM_001256017, NM_016363

CCDS: CCDS42626, CCDS46184, CCDS58678

Canonical transcript exons

ENST00000417454 — 8 exons

Exon	Start	End
ENSE00000727705	55018652	55018711
ENSE00000856424	55027578	55027862
ENSE00000856427	55032506	55032538
ENSE00001052325	55038203	55038264
ENSE00001252668	55025218	55025271
ENSE00003508016	55015683	55015733
ENSE00003563719	55032139	55032396
ENSE00003585199	55013705	55015165

Expression profiles

Bgee: expression breadth ubiquitous, 126 present calls, max score 84.76.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.9269 / max 105.4649, expressed in 106 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182672	0.4687	94
182673	0.2179	64
182674	0.1851	49
182675	0.0552	27

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	84.76	gold quality
leukocyte	CL:0000738	83.86	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.00	gold quality
lower esophagus mucosa	UBERON:0035834	73.78	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	72.35	gold quality
blood	UBERON:0000178	71.36	gold quality
granulocyte	CL:0000094	71.11	gold quality
cerebellar hemisphere	UBERON:0002245	70.68	gold quality
cerebellar cortex	UBERON:0002129	70.62	gold quality
cerebellum	UBERON:0002037	70.52	gold quality
right hemisphere of cerebellum	UBERON:0014890	69.87	gold quality
bone marrow cell	CL:0002092	67.28	gold quality
bone marrow	UBERON:0002371	66.93	gold quality
primary visual cortex	UBERON:0002436	65.40	gold quality
skin of abdomen	UBERON:0001416	63.60	gold quality
Brodmann (1909) area 9	UBERON:0013540	63.28	gold quality
right frontal lobe	UBERON:0002810	63.02	gold quality
esophagus mucosa	UBERON:0002469	62.80	gold quality
zone of skin	UBERON:0000014	62.61	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	62.53	gold quality
right lung	UBERON:0002167	62.19	gold quality
anterior cingulate cortex	UBERON:0009835	61.95	gold quality
skin of leg	UBERON:0001511	61.89	gold quality
left testis	UBERON:0004533	61.72	gold quality
testis	UBERON:0000473	61.43	gold quality
heart left ventricle	UBERON:0002084	61.33	gold quality
right testis	UBERON:0004534	61.29	gold quality
mucosa of transverse colon	UBERON:0004991	61.13	gold quality
vagina	UBERON:0000996	60.60	gold quality
superior frontal gyrus	UBERON:0002661	60.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.55

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETS1, FLI1, GATA1, SP1

miRNA regulators (miRDB)

40 targeting GP6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-4328	99.57	71.06	4094

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• First cloning of GPVI from platelet cDNA via protein sequence (PMID:10506151)
• regulates protein kinase B in platelets (PMID:11825911)
• Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling (PMID:11943772)
• Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP (PMID:11964287)
• Mean GPIV expression was 90% in adult reticulated platelets, 71% in adult mature platelets, 78% in cord reticulated platelets and 57% in cord mature platelets. (PMID:11990697)
• calmodulin binds to its cytoplasmic domain (PMID:12010829)
• collagen receptor glycoprotein VI and alphaIIbbeta3 trigger distinct patterns of receptor signalling in platelets, leading to tyrosine phosphorylation of PLCgamma2 (integrin alphaiibbeta3) (PMID:12049640)
• GPVI only reacts with fibrous collagen (PMID:12356768)
• induction of promoter by thrombopoietin and regulation by GATA-1, Fli-1, and Sp1 (PMID:12359731)
• Physical and functional interaction between cell-surface calreticulin and the collagen receptors integrin alpha2beta1 and glycoprotein VI in human platelets (PMID:12362238)
• The GP6 sequence -191 to -39 represents the core promoter; transcription is driven largely by GATA-1 (-176) and c-Ets-1 (-45) sites within this segment. (PMID:12377757)
• observed a 3-fold difference in the response to CRP-XL in platelet aggregation when comparing platelets from 10 high-frequency GP6 allele homozygotes with 8 low-frequency ones. (PMID:12560230)
• identification of discrete domains within the receptor’s intracellular tail that mediate interaction with Fc Rgamma, calmodulin, and Src family tyrosine kinases (PMID:12594225)
• Review. Platelet adhesion to collagen requires prior activation of integrins through “inside-out” signals generated by GPVI. GPVI acts in concert with other receptors and signaling pathways to initiate hemostasis and arterial thrombosis. (PMID:12649139)
• a region in the glycoprotein VI tail is required for association with the Fc receptor gamma-chain (PMID:12847105)
• GPVI was expressed in cultured HUVEC cells at both transcript and protein levels. Since HUVEC lack FcRgamma chain that forms complex with GPVI in platelets for signaling process, the function of GPVI in vascular endothelial cells remains to be determined. (PMID:12850831)
• the major role of alpha(2)beta(1) is to increase the avidity of collagen for the platelet surface and by doing so enhance activation of GPVI (PMID:12871331)
• results of a case-control study involving 180 stroke patients and 172 controls do not support a role for the integrin alpha2 C807T and GPVI Q317L polymorphisms in the development of first-ever ischemic stroke (PMID:12871362)
• The position of lysine59 on the apical surface of GPVI suggests a mode of collagen-related peptide binding analogous to that used by the related killer cell Ig-like receptors to bind HLA. (PMID:14504096)
• human platelet deposition on collagen depends on the concerted interplay of several receptors: GPIb in synergy with alpha(2)beta(1) mediating primary adhesion, reinforced by activation through GPVI, which further regulates the thrombus formation. (PMID:14563646)
• critical role of the collagen receptor GPVI in the initiation of thrombus formation at sites of vascular injury and identify soluble GPVI as a promising antithrombotic strategy (PMID:14656994)
• a central role for the FcR chain-associated GPVI collagen receptor in activation of platelet 12-H(P)ETE generation via 12-lipoxygenase. (PMID:15142951)
• GPVI is able to support synergy with vWF. (PMID:15203711)
• GPVI-mediated platelet activation plays a key role in the formation of platelet-derived microparticles in the presence of physiological Ca2+ in whole blood (PMID:15203713)
• GPVI stimulation caused activation of alpha2beta1 & alphaIIbbeta3 during collagen-induced thrombus formation. GPVI blockade reduced integrin activation along with aggregate formation & fibrinogen binding but not alpha2beta1-dependent adhesion. (PMID:15231520)
• alpha2beta1 integrin and GPVI regulate stress fiber formation in megakarocytes, the primary actin structures needed for cell contraction (PMID:15265786)
• Inhibition of GPVI may be a promising pharmacological target in the treatment of high-risk diabetic patients. (PMID:15277394)
• The gene for glycoprotein VI was shown to contribute to variation in platelet count. (PMID:15280902)
• role of this GPVI polymorphism, or another linked polymorphism, as a possible predictor of the risk of coronary thrombosis. (PMID:15306180)
• findings suggest that disruption of calmodulin binding to receptor cytoplasmic tails by agonist binding to the receptor triggers metalloproteinase-mediated loss of GPVI from the platelet surface (PMID:15308568)
• Induction of GP VI cleavage caused specific down-regulation of collagen-induced platelet aggregation, providing a mechanism for the modulation of platelet responsiveness to this important platelet agonist (PMID:15339851)
• results demonstrate that Vav3 and Vav1 play crucial but redundant roles in the activation of phospholipase C gamma 2 by glycoprotein GPVI (PMID:15456756)
• Site-directed mutagenesis revealed that valine 34 and leucine 36 are critical for GPVI interaction with collagen and collagen-related peptides. (PMID:15466473)
• Study finds by intravital fluorescence microscopy and ultrasonic flow measurements that GPVI extracellular domain fused to the immunoglobulin Fc domain (GPVI-Fc) has no effect on platelet adhesion and thrombus formation at the injured arterial wall. (PMID:15507524)
• c-Cbl plays a regulatory role in glycoprotein VI (GPVI)/Fc receptor gamma (FcRgamma)-chain-dependent platelet activation through its interaction with Syk (PMID:15701717)
• megakaryocyte-specific expression of the GP6 gene is regulated, in part, by CpG demethylation, which can be directly initiated by TPO (PMID:15701720)
• the association involves an interaction between the ectodomains of GPIb alpha and GPVI (PMID:15841318)
• studies establish platelet-collagen responses under physiologic flow as the consequence of a close partnership between 2 structurally distinct receptors, glycoprotein VI and integrin alpha2beta1 (PMID:15886326)
• results indicate that morphologically diverse collagen type I- and collagen type III-containing structures in lipid-rich atherosclerotic plaques stimulate thrombus formation by activating platelet glycoprotein VI (GPVI) (PMID:15923400)
• In advanced plaques collagen type I is major trigger of thrombus formation and phosphatidylserine exposure, acting via GPVI and ADP release, while tissue factor directly enhances coagulation. (PMID:15939050)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gp6	ENSMUSG00000078810
rattus_norvegicus	Gp6	ENSRNOG00000047204

Paralogs (25): LILRB1 (ENSG00000104972), LILRA1 (ENSG00000104974), LILRB5 (ENSG00000105609), A1BG (ENSG00000121410), KIR2DL1 (ENSG00000125498), LILRB2 (ENSG00000131042), IGSF1 (ENSG00000147255), LAIR2 (ENSG00000167618), KIR3DL1 (ENSG00000167633), OSCAR (ENSG00000170909), FCAR (ENSG00000186431), LILRB4 (ENSG00000186818), LILRA5 (ENSG00000187116), KIR2DL4 (ENSG00000189013), VSTM1 (ENSG00000189068), NCR1 (ENSG00000189430), LILRB3 (ENSG00000204577), KIR2DS4 (ENSG00000221957), LILRA4 (ENSG00000239961), LILRA2 (ENSG00000239998), KIR3DL2 (ENSG00000240403), KIR3DL3 (ENSG00000242019), KIR2DL3 (ENSG00000243772), LILRA6 (ENSG00000244482), TARM1 (ENSG00000248385)

Protein

Protein identifiers

Platelet glycoprotein VI — Q9HCN6 (reviewed: Q9HCN6)

Alternative names: Glycoprotein 6

All UniProt accessions (2): Q9HCN6, K7EIW7

UniProt curated annotations — full annotation on UniProt →

Function. Collagen receptor involved in collagen-induced platelet adhesion and activation. Plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus formation. The signaling pathway involves the FcR gamma-chain, the Src kinases (likely FYN or LYN) and SYK, the adapter protein LAT and leads to the activation of PLCG2.

Subunit / interactions. Associated with Fc receptor gamma chain. The GPVI:FcRgamma complex is associated with the Src kinase family FYN and LYN. Interacts with TRAF4. Interacts with COL1A1, but not with COL4A4. (Microbial infection) Interacts with Staphylococcus aureus protein SSL5.

Subcellular location. Cell membrane Cell membrane.

Tissue specificity. Megakaryocytes and platelets.

Post-translational modifications. N-linked glycosylation at Asn-92 is not required for the cell surface expression, but contributes to maximal adhesion to type I collagen, collagen-related peptide (CRP), and, to a lesser extent, to the snake venom C-type lectin convulxin (CVX).

Disease relevance. Bleeding disorder, platelet-type, 11 (BDPLT11) [MIM:614201] A mild to moderate bleeding disorder caused by defective platelet activation and aggregation in response to collagen. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Has no transmembrane domain. Does not interact with Fc receptor gamma chain. Does not bind to collagen-like peptides.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9HCN6-1	1, VI-1	yes
Q9HCN6-2	2, VI-2
Q9HCN6-3	3, VI-3

RefSeq proteins (3): NP_001077368, NP_001242946, NP_057447* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050412	Ig-like_Receptors_ImmuneReg	Family

Pfam: PF13895, PF13927

UniProt features (54 total): strand 17, sequence variant 8, mutagenesis site 7, sequence conflict 4, disulfide bond 2, splice variant 2, topological domain 2, turn 2, helix 2, domain 2, signal peptide 1, chain 1, transmembrane region 1, region of interest 1, compositionally biased region 1, glycosylation site 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
5OU7	X-RAY DIFFRACTION	1.9
7R58	X-RAY DIFFRACTION	1.9
2GI7	X-RAY DIFFRACTION	2.4
5OU8	X-RAY DIFFRACTION	2.5
5OU9	X-RAY DIFFRACTION	2.5
7NMU	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCN6-F1	76.52	0.55

Antibody-complex structures (SAbDab): 2 — 7NMU, 7R58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 48–88, 134–180

Glycosylation sites (1): 92

Mutagenesis-validated functional residues (7):

Position	Phenotype
61	increases collagen binding.
79	dramatically reduces collagen binding.
80	reduces collagen binding.
92	reduces collagen binding (65 to 70%).
94	reduces collagen binding (65 to 70%).
95	no effect on collagen binding.
186	reduces collagen binding.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-114604	GPVI-mediated activation cascade
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-75892	Platelet Adhesion to exposed collagen

MSigDB gene sets: 132 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, MULLIGHAN_NPM1_SIGNATURE_3_UP, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GOBP_PLATELET_ACTIVATION, GOCC_CELL_SURFACE, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_WOUND_HEALING, GOBP_CELL_CELL_ADHESION, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_REGULATION_OF_PLATELET_AGGREGATION, GOBP_POSITIVE_REGULATION_OF_CELL_CELL_ADHESION, GOBP_REGULATION_OF_HOMOTYPIC_CELL_CELL_ADHESION, GOBP_HOMOTYPIC_CELL_CELL_ADHESION, GOBP_HEMOSTASIS, GOBP_REGULATION_OF_PLATELET_ACTIVATION

GO Biological Process (9): immune response-regulating signaling pathway (GO:0002764), enzyme-linked receptor protein signaling pathway (GO:0007167), platelet activation (GO:0030168), collagen-activated tyrosine kinase receptor signaling pathway (GO:0038063), collagen-activated signaling pathway (GO:0038065), platelet aggregation (GO:0070527), positive regulation of platelet aggregation (GO:1901731), blood coagulation (GO:0007596), hemostasis (GO:0007599)

GO Molecular Function (6): transmembrane signaling receptor activity (GO:0004888), collagen binding (GO:0005518), signaling receptor activity (GO:0038023), collagen receptor activity (GO:0038064), protein tyrosine kinase binding (GO:1990782), protein binding (GO:0005515)

GO Cellular Component (7): plasma membrane (GO:0005886), cell surface (GO:0009986), extracellular matrix (GO:0031012), membrane raft (GO:0045121), extracellular exosome (GO:0070062), tetraspanin-enriched microdomain (GO:0097197), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Hemostasis	2
Platelet activation, signaling and aggregation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell surface receptor signaling pathway	2
collagen-activated signaling pathway	2
signal transduction	1
regulation of immune response	1
cell activation	1
blood coagulation	1
cell surface receptor protein tyrosine kinase signaling pathway	1
platelet activation	1
homotypic cell-cell adhesion	1
positive regulation of homotypic cell-cell adhesion	1
platelet aggregation	1
regulation of platelet aggregation	1
hemostasis	1
wound healing	1
coagulation	1
regulation of body fluid levels	1
signaling receptor activity	1
protein-containing complex binding	1
molecular transducer activity	1
transmembrane signaling receptor activity	1
collagen binding	1
protein kinase binding	1
binding	1
membrane	1
cell periphery	1
external encapsulating structure	1
membrane microdomain	1
extracellular vesicle	1
plasma membrane	1

Protein interactions and networks

STRING

1380 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GP6	FCER1G	P30273	999
GP6	VWF	P04275	997
GP6	ITGA2	P17301	975
GP6	LGALS3	P17931	974
GP6	S100A10	P08206	954
GP6	COL8A2	P25067	949
GP6	GP5	P40197	949
GP6	COL8A1	P27658	945
GP6	FN1	P02751	932
GP6	FYN	P06241	920
GP6	GP1BA	P07359	917
GP6	LYN	P07948	903
GP6	SELP	P16109	897
GP6	ITGA2B	P08514	893
GP6	PLCG2	P16885	880

IntAct

19 interactions, top by confidence:

A	B	Type	Score
GP6	LYN	psi-mi:“MI:0915”(physical association)	0.640
GP6	FYN	psi-mi:“MI:0914”(association)	0.560
GP6	FYN	psi-mi:“MI:0915”(physical association)	0.560
GP6	CALM1	psi-mi:“MI:0915”(physical association)	0.520
CALM1	GP6	psi-mi:“MI:0915”(physical association)	0.520
GP6	YES1	psi-mi:“MI:0915”(physical association)	0.400
FCER1G	GP6	psi-mi:“MI:0915”(physical association)	0.400
GP6	BTNL8	psi-mi:“MI:0915”(physical association)	0.400
GP6	FGFRL1	psi-mi:“MI:0915”(physical association)	0.400
FSTL5	GP6	psi-mi:“MI:0915”(physical association)	0.400
IL23A	GP6	psi-mi:“MI:0915”(physical association)	0.400
GP6	IL6R	psi-mi:“MI:0915”(physical association)	0.400
KIR2DS4	GP6	psi-mi:“MI:0915”(physical association)	0.400
PILRA	GP6	psi-mi:“MI:0915”(physical association)	0.400
GP6	SEMA3G	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (17): GP6 (Affinity Capture-RNA), GP6 (Proximity Label-MS), LYN (Reconstituted Complex), FYN (Reconstituted Complex), LYN (Affinity Capture-Western), GP6 (Synthetic Lethality), CALM1 (Affinity Capture-Western), LYN (Affinity Capture-Western), FCER1G (Affinity Capture-Western), TRAF4 (Affinity Capture-Western), TGFB1I1 (Affinity Capture-Western), NCF1 (Affinity Capture-Western), PTK2B (Affinity Capture-Western), LYN (Affinity Capture-Western), GP6 (Affinity Capture-Western)

ESM2 similar proteins: A0A0K2S4Q6, A2A7V7, A6NI73, A8K4G0, O43699, O75019, O75022, O75023, O75871, O76036, P0C191, P20138, P24071, P40198, P59901, P80943, Q08708, Q13410, Q28110, Q3U497, Q496F6, Q64JA4, Q6GTX8, Q6ISS4, Q6PI73, Q6UXZ3, Q7TSN2, Q863H2, Q8C567, Q8K249, Q8MJZ2, Q8MJZ7, Q8N149, Q8N423, Q8N6C8, Q8NHJ6, Q8NHL6, Q8VBT3, Q8VCH2, Q95JB9

Diamond homologs: A0A0G2KBC9, A6NI73, C0HJX2, C0HJX3, D3ZQX2, O75019, O75022, O75023, O76036, P0C191, P24071, P43626, P43629, P43630, P59901, P83556, P97484, Q14943, Q14954, Q61450, Q64281, Q6GTX8, Q6ISS4, Q6PI73, Q7TQA1, Q863H2, Q8C567, Q8IYS5, Q8MJZ2, Q8MJZ7, Q8N109, Q8N149, Q8N423, Q8N6C8, Q8N743, Q8NHJ6, Q8NHK3, Q8NHL6, Q95JB9, Q9HCN6

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
GATA1	“up-regulates quantity by expression”	GP6	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	GP6	“transcriptional regulation”
FLI1	“up-regulates quantity by expression”	GP6	“transcriptional regulation”
SP1	“up-regulates quantity by expression”	GP6	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

354 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	13
Likely pathogenic	5
Uncertain significance	147
Likely benign	117
Benign	50

Top pathogenic / likely-pathogenic (18)

Variant ID	HGVS	Classification
1071188	NM_016363.5(GP6):c.171C>G (p.Tyr57Ter)	Pathogenic
1072837	NM_016363.5(GP6):c.711dup (p.Val238fs)	Pathogenic
2720135	NM_016363.5(GP6):c.548dup (p.Ser184fs)	Pathogenic
2789712	NM_016363.5(GP6):c.472G>T (p.Glu158Ter)	Pathogenic
287607	NM_016363.5(GP6):c.479G>A (p.Trp160Ter)	Pathogenic
2903349	NM_016363.5(GP6):c.543C>A (p.Tyr181Ter)	Pathogenic
2959947	NM_016363.5(GP6):c.572G>A (p.Trp191Ter)	Pathogenic
30504	NM_016363.5(GP6):c.356_360dup (p.Gly121fs)	Pathogenic
30506	NM_016363.5(GP6):c.142_157del (p.Cys48fs)	Pathogenic
3674675	NM_016363.5(GP6):c.254_255insTAGG (p.Tyr86fs)	Pathogenic
3697091	NM_016363.5(GP6):c.438C>G (p.Tyr146Ter)	Pathogenic
4691208	NM_016363.5(GP6):c.64_65del (p.Ser22fs)	Pathogenic
831173	NC_000019.10:g.(?55025218)(55038236_?)del	Pathogenic
2019957	NM_016363.5(GP6):c.610+2T>G	Likely pathogenic
3657322	NM_016363.5(GP6):c.725-1G>C	Likely pathogenic
3657432	NM_016363.5(GP6):c.67+2T>G	Likely pathogenic
3712998	NM_016363.5(GP6):c.611-1G>A	Likely pathogenic
4542367	NM_016363.5(GP6):c.48del (p.Arg17fs)	Likely pathogenic

SpliceAI

1495 predictions. Top by Δscore:

Variant	Effect	Δscore
19:55015677:A:AC	donor_gain	1.0000
19:55015678:C:CC	donor_gain	1.0000
19:55015678:CT:C	donor_gain	1.0000
19:55015732:CT:C	acceptor_gain	1.0000
19:55015734:C:CC	acceptor_gain	1.0000
19:55018709:ATT:A	acceptor_gain	1.0000
19:55018710:TT:T	acceptor_gain	1.0000
19:55018712:C:CC	acceptor_gain	1.0000
19:55015166:C:CA	acceptor_loss	0.9900
19:55015166:C:CC	acceptor_gain	0.9900
19:55015678:CTCA:C	donor_gain	0.9900
19:55015679:TCA:T	donor_loss	0.9900
19:55015680:CAC:C	donor_loss	0.9900
19:55015681:ACCA:A	donor_loss	0.9900
19:55015682:CCAG:C	donor_gain	0.9900
19:55015729:AGTCT:A	acceptor_gain	0.9900
19:55015730:GTCT:G	acceptor_gain	0.9900
19:55015733:TCTGG:T	acceptor_loss	0.9900
19:55018645:TAC:T	donor_loss	0.9900
19:55018646:ACT:A	donor_loss	0.9900
19:55018647:CTCA:C	donor_loss	0.9900
19:55018648:T:TA	donor_loss	0.9900
19:55018649:C:CG	donor_loss	0.9900
19:55018650:A:AC	donor_gain	0.9900
19:55018650:A:T	donor_loss	0.9900
19:55018651:C:CC	donor_gain	0.9900
19:55018707:GAATT:G	acceptor_gain	0.9900
19:55018708:AATT:A	acceptor_gain	0.9900
19:55018713:T:G	acceptor_loss	0.9900
19:55027860:CTC:C	acceptor_gain	0.9900

AlphaMissense

2135 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:55027787:C:G	C134S	0.994
19:55027788:A:T	C134S	0.994
19:55032321:C:G	C48S	0.994
19:55032322:A:T	C48S	0.994
19:55027639:G:C	F183L	0.993
19:55027639:G:T	F183L	0.993
19:55027641:A:G	F183L	0.993
19:55027656:A:C	Y178D	0.993
19:55032291:C:G	R58P	0.992
19:55027649:C:G	C180S	0.991
19:55027650:A:T	C180S	0.991
19:55032201:C:G	C88S	0.991
19:55032202:A:T	C88S	0.991
19:55027788:A:G	C134R	0.990
19:55027694:A:C	F165C	0.989
19:55032322:A:G	C48R	0.989
19:55027650:A:G	C180R	0.988
19:55027642:G:C	S182R	0.987
19:55027642:G:T	S182R	0.987
19:55027644:T:G	S182R	0.987
19:55027648:G:C	C180W	0.987
19:55027759:A:C	F143L	0.987
19:55027759:A:T	F143L	0.987
19:55027761:A:G	F143L	0.987
19:55032202:A:G	C88R	0.987
19:55027603:G:C	S195R	0.986
19:55027603:G:T	S195R	0.986
19:55027605:T:G	S195R	0.986
19:55032150:A:T	L105H	0.986
19:55027786:A:C	C134W	0.984

dbSNP variants (sampled 300 via entrez): RS1000007956 (19:55017958 C>T), RS1000040332 (19:55036351 T>C), RS1000297837 (19:55020582 G>A), RS1000436377 (19:55035965 C>A,G,T), RS1000498501 (19:55015942 A>G), RS1000612224 (19:55019205 A>G), RS1000686126 (19:55021066 A>T), RS1000737976 (19:55021190 C>G), RS1000753751 (19:55026354 T>C,G), RS1000852502 (19:55015422 T>G), RS1001013215 (19:55025622 C>T), RS1001122928 (19:55018215 G>A,T), RS1001209065 (19:55026538 G>T), RS1001312128 (19:55031739 C>T), RS1001415006 (19:55028954 C>T)

Disease associations

OMIM: gene MIM:605546 | disease phenotypes: MIM:614201

GenCC curated gene-disease

Disease	Classification	Inheritance
platelet-type bleeding disorder 11	Strong	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
platelet-type bleeding disorder 11	Definitive	AR

Mondo (2): platelet-type bleeding disorder 11 (MONDO:0013623), thrombocytopenia (MONDO:0002049)

Orphanet (2): Bleeding diathesis due to a collagen receptor defect (Orphanet:73271), Bleeding diathesis due to glycoprotein VI deficiency (Orphanet:98885)

HPO phenotypes

10 total (10 of 10 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000132	Menorrhagia
HP:0000421	Epistaxis
HP:0000978	Bruising susceptibility
HP:0003010	Prolonged bleeding time
HP:0003593	Infantile onset
HP:0008320	Impaired collagen-induced platelet aggregation
HP:0011871	Impaired ristocetin-induced platelet aggregation
HP:0011873	Abnormal platelet count
HP:0031364	Ecchymosis

GWAS associations

21 associations (top):

Study	Trait	p-value
GCST000693_12	Platelet aggregation	8.000000e-14
GCST004599_156	Mean platelet volume	9.000000e-28
GCST004616_48	Platelet distribution width	8.000000e-45
GCST004619_92	Reticulocyte fraction of red cells	3.000000e-09
GCST004622_81	Reticulocyte count	8.000000e-11
GCST006035_17	Breast cancer and/or colorectal cancer	3.000000e-06
GCST006585_1194	Blood protein levels	7.000000e-150
GCST008171_11	Platelet aggregation	2.000000e-08
GCST008171_6	Platelet aggregation	1.000000e-09
GCST008171_7	Platelet aggregation	1.000000e-09
GCST008171_8	Platelet aggregation	3.000000e-09
GCST009030_30	Venous thromboembolism	3.000000e-09
GCST90000584_16	Inflammatory biomarkers (multivariate analysis)	9.000000e-14
GCST90002385_520	High light scatter reticulocyte count	1.000000e-28
GCST90002386_217	High light scatter reticulocyte percentage of red cells	6.000000e-26
GCST90002395_421	Mean platelet volume	7.000000e-69
GCST90002397_440	Mean spheric corpuscular volume	1.000000e-09
GCST90002401_298	Platelet distribution width	2.000000e-143
GCST90002402_573	Platelet count	3.000000e-09
GCST90002405_434	Reticulocyte count	3.000000e-37
GCST90002406_537	Reticulocyte fraction of red cells	2.000000e-34

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007984	platelet component distribution width
EFO:0007986	reticulocyte count
EFO:0004872	inflammatory biomarker measurement
EFO:0004309	platelet count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013921	Thrombocytopenia	C15.378.140.855; C15.378.243.937

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3308912 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

9 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 306,397 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1069	VALSARTAN	4	38,585
CHEMBL1873475	IBRUTINIB	4	7,994
CHEMBL191	LOSARTAN	4	88,932
CHEMBL3707348	ACALABRUTINIB	4	4,504
CHEMBL3936761	ZANUBRUTINIB	4	2,484
CHEMBL4071161	TIRABRUTINIB	4	2,170
CHEMBL4072833	EVOBRUTINIB	3	960
CHEMBL18786	CINANSERIN	2	580
CHEMBL96	GAMMA-AMINOBUTYRIC ACID	1	160,188

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1613662	Efficacy	3	aspirin	Coronary Artery Disease

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1613662	GP6	3	2.50	1	aspirin

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
Glaucocalyxin A	IC50	21 nM

ChEMBL bioactivities

17 potent at pChembl≥5 of 34 total, top 16 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.70	IC50	2	nM	GLAUCOCALYXIN A
7.68	IC50	21	nM	GLAUCOCALYXIN A
7.51	IC50	31	nM	CHEMBL1235110
7.39	Kd	41.1	nM	GAMMA-AMINOBUTYRIC ACID
7.32	IC50	48	nM	CHEMBL1235110
6.92	IC50	120	nM	IBRUTINIB
6.29	IC50	510	nM	ZANUBRUTINIB
6.24	IC50	570	nM	CHEMBL1235110
5.92	IC50	1210	nM	ACALABRUTINIB
5.92	IC50	1200	nM	TIRABRUTINIB
5.40	IC50	4000	nM	LOSARTAN
5.24	IC50	5700	nM	CHEMBL3959435
5.23	IC50	5840	nM	EVOBRUTINIB
5.17	IC50	6700	nM	CHEMBL3959435
5.12	IC50	7600	nM	CHEMBL308493
5.05	IC50	9000	nM	S007-1558 (S)

PubChem BioAssay actives

17 with measured affinity, of 66 total; 12 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(1R,2R,4S,9R,10S,13S,16R)-2,16-dihydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-6,15-dione	1692275: Antagonist activity at GP6 in human platelet assessed as reduction in CRP-induced platelet-aggregation preincubated for 10 mins followed by collagen stimulation by aggregometry	ic50	0.0020	uM
2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-(3-methylanilino)pyrimidine-5-carboxamide	1692283: Modulation of GP6 in human platelets assessed as reduction in convulxin-induced platelet aggregation	ic50	0.0310	uM
.gamma.-aminobutyric acid	1692270: Binding affinity to human platelet lysate GP6 at 0.1 uM by surface plasmon resonance analysis	kd	0.0411	uM
Ibrutinib	1692287: Inhibition of GP6 in human whole blood assessed as protein-mediated platelet aggregation preincubated for 15 mins followed by collagen stimulation and measured for 10 mins by multiple electrode aggregometry	ic50	0.1200	uM
Zanubrutinib	1692287: Inhibition of GP6 in human whole blood assessed as protein-mediated platelet aggregation preincubated for 15 mins followed by collagen stimulation and measured for 10 mins by multiple electrode aggregometry	ic50	0.5100	uM
6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one	1692287: Inhibition of GP6 in human whole blood assessed as protein-mediated platelet aggregation preincubated for 15 mins followed by collagen stimulation and measured for 10 mins by multiple electrode aggregometry	ic50	1.2000	uM
Acalabrutinib	1692287: Inhibition of GP6 in human whole blood assessed as protein-mediated platelet aggregation preincubated for 15 mins followed by collagen stimulation and measured for 10 mins by multiple electrode aggregometry	ic50	1.2100	uM
Losartan	1692277: Antagonist activity at GP6 in human platelet assessed as reduction in collagen-induced platelet-aggregation preincubated for 60 secs followed by collagen stimulation by light transmission aggregometry	ic50	4.0000	uM
2-(4-methoxyphenyl)sulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxamide	1339062: Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of CVX-induced platelet aggregation preincubated for 5 mins followed by CVX addition measured after 5 mins by turbidimetric method	ic50	5.7000	uM
1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one	1692287: Inhibition of GP6 in human whole blood assessed as protein-mediated platelet aggregation preincubated for 15 mins followed by collagen stimulation and measured for 10 mins by multiple electrode aggregometry	ic50	5.8400	uM
2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carbaldehyde	1339061: Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of CRP-XL-induced platelet aggregation preincubated for 5 mins followed by CRP-XL addition measured after 5 mins by turbidimetric method	ic50	7.6000	uM
(3S)-2-(4-methoxyphenyl)sulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxamide	1339062: Antagonist activity at GP6 receptor in human platelet rich plasma assessed as inhibition of CVX-induced platelet aggregation preincubated for 5 mins followed by CVX addition measured after 5 mins by turbidimetric method	ic50	9.0000	uM

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
Aspirin	decreases response to substance	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression	1
Cannabinoids	affects methylation, increases abundance	1
T-2 Toxin	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Vitamin E	decreases expression	1
Aflatoxin B1	increases methylation	1
S-Nitrosoglutathione	increases expression	1

ChEMBL screening assays

32 unique, capped per target: 32 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1064399	Binding	Binding affinity to human N-terminal Ig-like domain D1D2 GPVI expressed in Escherichia coli DH5alpha by NMR spectroscopy	Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. — J Med Chem

Clinical trials (associated diseases)

240 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00039858	PHASE4	COMPLETED	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
NCT00239733	PHASE4	TERMINATED	Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
NCT00907478	PHASE4	COMPLETED	Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT01727401	PHASE4	TERMINATED	Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia
NCT02032134	PHASE4	TERMINATED	Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
NCT02267993	PHASE4	COMPLETED	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
NCT03633019	PHASE4	UNKNOWN	High-dose Use of rhTPO in CIT Patients
NCT03688191	PHASE4	UNKNOWN	Study of Sirolimus in CTD-TP in China
NCT04906083	PHASE4	UNKNOWN	Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
NCT05217719	PHASE4	UNKNOWN	Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05382013	PHASE4	UNKNOWN	Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
NCT05944458	PHASE4	COMPLETED	Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients
NCT06562738	PHASE4	RECRUITING	Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
NCT00037791	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00039910	PHASE3	COMPLETED	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00073580	PHASE3	COMPLETED	Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
NCT00102323	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102336	PHASE3	COMPLETED	AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00116688	PHASE3	COMPLETED	Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00128713	PHASE3	COMPLETED	Optimal Platelet Dose Strategy for Management of Thrombocytopenia
NCT00151866	PHASE3	COMPLETED	Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
NCT00261924	PHASE3	COMPLETED	Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
NCT00415532	PHASE3	COMPLETED	Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00420914	PHASE3	TERMINATED	Strategies for Transfusion of Platelets (SToP)
NCT00501345	PHASE3	TERMINATED	Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
NCT00508820	PHASE3	COMPLETED	An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00678587	PHASE3	TERMINATED	Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
NCT01438840	PHASE3	COMPLETED	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01805648	PHASE3	UNKNOWN	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
NCT02244658	PHASE3	UNKNOWN	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
NCT02389621	PHASE3	COMPLETED	Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
NCT02444728	PHASE3	TERMINATED	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
NCT02487563	PHASE3	COMPLETED	Prospective Study of Patients With Thrombocytopenia Following HSCT
NCT02578901	PHASE3	COMPLETED	American Trial Using Tranexamic Acid in Thrombocytopenia
NCT03326843	PHASE3	TERMINATED	Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
NCT03515096	PHASE3	COMPLETED	Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
NCT05563064	PHASE3	UNKNOWN	Effect of Herbal Formulation on Thrombocytes Count
NCT07442513	PHASE3	RECRUITING	Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT